Pegloticase Plus Methotrexate Gets Priority Review for Uncontrolled Gout
The sBLA submission is supported by data from the phase 4 MIRROR trial.
The sBLA submission is supported by data from the phase 4 MIRROR trial.
The comparative efficacy of these therapies has been extended to patients with stage 3 chronic kidney disease, a common comorbidity in gout.
Researchers assessed the incidence and potential risk factors for the development of
fenofibrate-associated nephrotoxicity in patients with gout.
Although studies have demonstrated similar clinical features between chronic cough and chronic pain, the exact relationship has not been determined.
Over a quarter of patients with acute gout received a prescription for opioids at discharge from the emergency department.
Researchers provided participants in the intervention group with gout education, podiatric care, and an athletic shoe, and participants in the control arm received only gout education and podiatric care.
A diagnosis of incident or new chronic pain may be twice as likely in patients with vs without gout.
Corticosteroids appear to be a reasonable alternative to NSAIDs for the treatment of acute pain as a result of gout.
Ironwood announced the launch of Duzallo (lesinurad/allopurinol) tablets for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone.
The FDA approved Duzallo, a fixed-dose tablet combining lesinurad and allopurinol, for the treatment of uncontrolled gout.